Diagnosed with MS at age 32 in 1980, Ed has written the “MS Wire” column for Multiple Sclerosis News Today since August 2016. He presents timely information on MS, blended with personal experiences. Before retiring from full-time work in 2012, Tobias spent more than four decades in broadcast and on-line newsrooms as a manager, reporter, and radio news anchor. He’s won several national broadcast awards. As an MS patient communicator, Ed consults with healthcare and social media companies. He’s the author of “We’re Not Drunk, We Have MS: A tool kit for people living with multiple sclerosis.” Ed and his wife split time between the Washington, D.C. suburbs and Florida’s Gulf Coast.
Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Today I’ll focus on stories from the American Academy of Neurology (AAN) 2023 Annual Meeting, held April 22-27 in Boston. Here’s a look at…
Those with multiple sclerosis (MS) may want to roll up their sleeves again for a COVID-19 vaccine. I’m thinking about whether to join them. About 10 days ago, an advisory committee of the U.S. Centers for Disease Control and Prevention (CDC) supported a recommendation that people 65…
Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Yoga vs. physical therapy The MS News Today article “Yoga better than physical therapy at improving…
Oops! I took a turn too fast in the parking lot of my condo the other morning and tipped to the left. And with that, my mobility scooter and I headed for a fall. Do you know the feeling when something bad is about to happen and there’s nothing…
Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: EBV vaccine trial could start in 2024 The MS News Today story “Vaccine against Epstein-Barr virus…
Biogen has been a top dog in the multiple sclerosis (MS) treatment field for decades. The pharmaceutical giant developed Avonex (interferon beta-1a), approved in the U.S. in 1996 as one of the first disease-modifying therapies (DMTs) for MS. I remember how excited I was to be…
Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Good patient reviews for Sativex Sativex (nabiximols) is an oral cannabinoid spray designed to ease MS…
My exercise routine was first disrupted by the pandemic. Then Hurricane Ian landed a right hook on the exercise room in my Florida community, knocking it out of action. But not long after that, my thoughts were turning to something sweeter — pitchers and catchers returning to spring…
Welcome to “MS News Notes,” a Monday morning column in which I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: A positive report on orelabrutinib Orelabrutinib is one of several experimental Bruton’s tyrosine kinase (BTK)…
Many people with multiple sclerosis (MS) have experienced urinary tract infections (UTIs) at some point. It’s a common problem with MS and can be caused by a number of things, such as the inability to fully empty the bladder or the need to self-catheterize. Symptoms can include urinary…
Note: This column was updated March 30, 2023, to remove the statement that Briumvi is more potent than Ocrevus or Kesimpta as there have been no trials comparing the three therapies’ potency. Welcome to “MS News Notes,” a Monday morning column in which I comment on multiple sclerosis (MS)…
Boarding an aircraft before others is a small benefit to being a disabled flyer. For years, giving me a small start to get down the jetway ahead of even the most frequent of frequent flyers has given me time to get off the little scooter I use due to my…
Welcome to “MS News Notes,” a Monday morning column in which I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Study shows Ocrevus lowers risk of MS progression This seems to be just what the doctor ordered,…
Choosing the best disease-modifying therapy (DMT) to treat your multiple sclerosis (MS) can be a tough decision. When I was diagnosed with MS way back in 1980, it was easy. There were no DMTs to choose from. The first three — Avonex (interferon beta-1a), Betaseron…
Welcome to “MS News Notes,” a Monday morning column in which I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: A different type of stem cell transplant When stem cell transplant is mentioned to treat someone…
You may not have heard of Judy Heumann, who died March 4 at the age of 75. Although she’s not directly connected to the multiple sclerosis (MS) community, you should know about her. Everyone who lives with a disability owes her a great deal. At just 18 months old,…
Welcome to “MS News Notes,” a Monday morning column in which I comment on multiple sclerosis (MS) news stories that caught my eye last week. In this column, I’ll be highlighting more MS News Today articles from the Americas Committee for Treatment and Research in Multiple Sclerosis…
Want to reduce your multiple sclerosis (MS) fatigue? Maybe we should talk about it. I’m talking about a fatigue treatment called cognitive behavioral therapy (CBT), which usually involves changing a person’s thinking and behavior. By talking with a therapist, sometimes on the phone, a patient develops an…
Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. In this column, I’ll be highlighting some MS News Today stories from last week’s Americas Committee for Treatment and Research in Multiple Sclerosis…
If you have multiple sclerosis (MS), I’m sure you’ve had several MRIs by now. You’ve probably also had one using a contrast agent. The contrast agent is made from a rare earth element called gadolinium. Mixed with other chemical ions, it highlights lesions or areas…
Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: More remyelination research For years, most MS research has focused on stopping disease progression. In the past couple…
It was bound to happen. Even though it’s been more than three years since COVID-19 reared it head in Wuhan, China, and even though I’ve had five of the COVID-19 vaccine shots recommended by the U.S. Centers for Disease Control and Prevention — two primary series doses and three…
Welcome to “MS News Notes,” a weekly Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Older patients and DMTs The title of a report by MS News Today‘s Patricia Inacio notes…
Note: This column has been updated Feb. 15, 2023, to correct that Ocrevus is an infusion medication and is not similar to chemotherapy. Is treating multiple sclerosis (MS) really all about the medications? At least one neurologist thinks so, probably more, and I think that’s no way to practice…
Welcome to “MS News Notes,” a weekly Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Tysabri biosimilar on the horizon Tysabri (natalizumab) is a very effective disease-modifying therapy (DMT) for…
Have you ever heard of an ABLE savings account? I hadn’t until a couple weeks ago. The acronym stands for the Achieving a Better Life Experience Act, a law passed by the U.S. Congress in 2014. It created special savings accounts that allow disabled Americans, including people with…
Welcome to “MS News Notes,” a weekly Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: A protein to restore myelin? I usually don’t like to comment on stories about mouse studies, because…
A recent question on the MS News Today Facebook page generated some buzz about getting a buzz on to treat your multiple sclerosis (MS). The question was, “What helps you the most to manage your daily life with MS?” Many people with MS said the thing that helped…
Welcome to “MS News Notes,” where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Gilenya alternative The disease-modifying therapy (DMT) Gilenya (fingolimod) has been around since 2010. Now the U.S. Food and Drug Administration has…
As you read this, a group of scientists is doing multiple sclerosis (MS) research high above the earth. Their laboratory is in orbit about 250 miles up, aboard the International Space Station. Working with researchers at the New York Stem Cell Foundation (NYSCF), astronauts have been helping…
Get regular updates to your inbox.